Drug Trial Radar · NCT01345630
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
Last checked: Nov 19, 2026Latest source record: Jan 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
813
Actual
Start
Sep 2011
Primary completion
Aug 2013
Study completion Jan 2014
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- May 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.
Conditions
- HIV-1
Interventions
MaravirocDrug
Maraviroc tablet 150 mg once daily for 96 weeks.
Emtricitabine/tenofovirDrug
Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
darunavir/ritonavir 800/100 mgDrug
darunavir/ritonavir 800/100 mg
placebo for emtricitabine/tenofovirDrug
placebo for emtricitabine/tenofovir
placebo for maravirocDrug
placebo for maraviroc
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.Time frame: Week 48
Locations
177 sites in 19 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - 1917 Research Clinic
Birmingham, Alabama
Health Services Center
Hobson City, Alabama
Kaiser Permanente
Hayward, California
Cedars-Sinai Medical Center
Los Angeles, California
Dr. Anthony Mills, MD, Inc.
Los Angeles, California
Orange Coast Medical Group
Newport Beach, California
Desert Oasis Healthcare Medical Group
Palm Springs, California
University of California Davis Research
Sacramento, California
TICON I Research Clinic (DEXA Scan only)
Sacramento, California
Kaiser Hospital Sacramento
Sacramento, California
Synarc Inc.
San Francisco, California
Investigational Drugs Pharmacy
San Francisco, California
Kaiser Permanente - Clinical Trials Unit
San Francisco, California
Kaiser Permanente Santa Clara
Santa Clara, California
Kaiser Permanente
Union City, California
University of Colorado Denver - University of Colorado Hospital
Aurora, Colorado
Kaiser Permanente of Colorado
Denver, Colorado
Yale - New Haven Hospital Nathan Smith Clinic
New Haven, Connecticut
Yale University
New Haven, Connecticut
Circle CARE Center
Norwalk, Connecticut
Capital Medical Associates, PC
Washington D.C., District of Columbia
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
Broward Health - Comprehensive Care Center
Fort Lauderdale, Florida
Broward General Medical Center
Fort Lauderdale, Florida
The Kinder Medical Group
Miami, Florida
UMHC/Sylvester Comprehensive Cancer Center
Miami, Florida
University of Miami AIDS Clinical Research Unit
Miami, Florida
University of Miami
Miami, Florida
Community AIDS Resource Inc dba Care Resource
Miami, Florida
Miami Research Associates
Miami, Florida
Wohlfeiler, Piperato and Associates, LLC
Miami Beach, Florida
Infectious Diseases Associates of Northwest Florida, PA
Pensacola, Florida
St. Joseph's Hospital Diagnostic Center
Tampa, Florida
University of South Florida Health-HIV Clinical Research Unit
Tampa, Florida
Infectious Disease Research Institute, Inc.
Tampa, Florida
Osteoporosis Care Center
Tampa, Florida
Quest Diagnostic Laboratory
Tampa, Florida
Rowan Tree Medical, PA
Wilton Manors, Florida
AIDS Research Consortium of Atlanta
Atlanta, Georgia
DeKalb Medical Diagnostic Breast Center
Decatur, Georgia
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.